Everence Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Everence Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,090	Closed	-$564K	–	760
2024 Q2	$564K	Buy	2,090 +470	+29%	+$137K	0.04%	353
2024 Q1	$560K	Hold	1,620	–	–	0.04%	374
2023 Q4	$523K	Hold	1,620	–	–	0.04%	392
2023 Q3	$581K	Buy	1,620 +900	+125%	+$347K	0.05%	340
2023 Q2	$269K	Hold	720	–	–	0.02%	562
2023 Q1	$345K	Hold	720	–	–	0.03%	486
2022 Q4	$303K	Buy	720 +110	+18%	+$44.4K	0.03%	537
2022 Q3	$254K	Sell	610 -70	-10%	-$34.9K	0.02%	574
2022 Q2	$337K	Buy	+680	New	+$354K	0.03%	473
2022 Q1	–	Sell	-580	Closed	-$438K	–	736
2021 Q4	$438K	Sell	580 -420	-42%	-$314K	0.03%	467
2021 Q3	$746K	Hold	1,000	–	–	0.06%	258
2021 Q2	$644K	Hold	1,000	–	–	0.05%	315
2021 Q1	$571K	Hold	1,000	–	–	0.05%	323
2020 Q4	$583K	Buy	1,000 +500	+100%	+$285K	0.06%	298
2020 Q3	$258K	Buy	+500	New	+$253K	0.03%	511

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Everence Capital Management's BIO Position: Q3 2024 in Review

Everence Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 2,090 shares — an estimated $564K sold.

Everence Capital Management first reported a position in BIO in Q3 2020 and held it in 15 quarters. The position peaked at $746K in Q3 2021. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

Everence Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
Everence Capital Management sold 2,090 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $564K.
Everence Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 15 quarters.
Everence Capital Management's Bio-Rad Laboratories Class A position peaked at $746K in Q3 2021.
438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Everence Capital Management's 13F filing for Q3 2024, filed 21 Oct 2024.